Trump names son-in-law as senior presidential advisor

January 10, 2017

New York, Jan 10: US President-elect Donald Trump announced that his son-in-law Jared Kushner, a property developer and publisher, will serve as senior White House advisor, flouting myriad legal and ethical concerns.

T advisor The incoming Republican, who has never previously held elected office, said Kushner, who also has no political experience outside his father-in-law's campaign, would serve as "senior advisor to the president."

Kushner, whom Forbes estimates is worth USD 1.8 billion together with his parents and adult brother, will forego his salary while serving in the administration, said a statement from the transition team.

The 35-year-old will work closely with White House chief of staff Reince Priebus and chief strategist Steve Bannon to execute Trump's agenda, it added.

"Jared has been a tremendous asset and trusted advisor throughout the campaign and transition and I am proud to have him in a key leadership role in my administration," Trump announced yesterday.

"He has been incredibly successful, in both business and now politics. He will be an invaluable member of my team as I set and execute an ambitious agenda, putting the American people first," he added.

Priebus called Kushner "a visionary with a rare ability to communicate with and assemble broad coalitions of support" and said his "open mind, adaptability and keen intellect" would be a "great asset" to the team.

Kushner welcomed the appointment as "an honor" and said he was "humbled" by the opportunity to serve.

Comments

Good move by anogther Feku. Next he will appoint his sons as FBI chief, his sister in law as Home secretary, his Father in law as Bank of America chief, his mother in law as home minister etc etc. Good move. Keep going on dear and enjoy your stay as new President

Add new comment

Coastaldigest.com reserves the right to delete or block any comments.
Coastaldigset.com is not responsible for its readers’ comments.
Comments that are abusive, incendiary or irrelevant are strictly prohibited.
Please use a genuine email ID and provide your name to avoid reject.

Coronavirus medicine update: Decade-old Actemra emerges as hope for COVID-19 victims

News Network

March 4,2020

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Comments